About
This Hanmi Pharmaceuticals phase 1 trial evaluated the safety and pharmacokinetics of HM15275 in healthy and obese adults. The investigational drug was well tolerated with mostly mild GI side effects and no serious adverse events. Early data support weekly dosing and show promising weight reduction, supporting continued investigation into HM15275’s long-term efficacy and therapeutic value in obesity and cardiometabolic disease management.
The poster presentation was presented by Marcus Hompesch at the 2025 American Diabetes Association 85th Scientific Sessions in Chicago.
